Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Umakanth Vudumula, Mausam Patidar, Kapil Gudala, Elizabeth Karpf & Nicholas Adlard. (2023) Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. Journal of Medical Economics 26:1, pages 11-18.
Read now
Read now
Dirk Schriefer, Rocco Haase, Nils-Henning Ness & Tjalf Ziemssen. (2022) Cost of illness in multiple sclerosis by disease characteristics – A review of reviews. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 177-195.
Read now
Read now
J. L. Poveda, J. L. Trillo, C. Rubio-Terrés, D. Rubio-Rodríguez, A. Polanco & C. Torres. (2020) Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 20:3, pages 295-303.
Read now
Read now
Articles from other publishers (14)
Ricardo Ginestal, Carlos Rubio-Terrés, Olga Durán Morán, Darío Rubio-Rodríguez, Heidi De Los Santos, Cristina Ordoñez & Isabel Sánchez-Magro. (2023) Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain. Journal of Comparative Effectiveness Research 12:2.
Crossref
Crossref
Néboa Zozaya, Fernando Abdalla, Ignacio Casado Moreno, Carlos Crespo-Diz, Ana M. Ramírez Gallardo, Joaquín Rueda Soriano, Macarena Alcalá Galán & Álvaro Hidalgo-Vega. (2022) The economic burden of pulmonary arterial hypertension in Spain. BMC Pulmonary Medicine 22:1.
Crossref
Crossref
Steven Simoens. (2022) Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies. Frontiers in Neurology 13.
Crossref
Crossref
Nupur Greene, Lita Araujo, Cynthia Campos, Hannah Dalglish, Sarah Gibbs & Irina Yermilov. (2022) The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. Journal of Health Economics and Outcomes Research 9:2.
Crossref
Crossref
Mehdi Rezaee, Mohammad Hossein Morowvat, Maryam Poursadeghfard, Armin Radgoudarzi & Khosro Keshavarz. (2022) Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Services Research 22:1.
Crossref
Crossref
Nupur Greene, Lita Araujo, Cynthia Campos, Hannah Dalglish, Sarah Gibbs & Irina Yermilov. (2022) The Economic and Humanistic Burden of Pediatric-Onset Multiple Sclerosis. Journal of Health Economics and Outcomes Research, pages 103-114.
Crossref
Crossref
F. J. Carrera-Hueso, L. Álvarez-Arroyo, J. E. Poquet-Jornet, P. Vázquez-Ferreiro, R. Martínez-Gonzalbez, D. El-Qutob, M. A. Ramón-Barrios, F. Martínez-Martínez, J. L. Poveda-Andrés & C. Crespo-Palomo. (2021) Hospitalization budget impact during the COVID-19 pandemic in Spain. Health Economics Review 11:1.
Crossref
Crossref
Kevin Morris, Mohammad Nami, Joe F. Bolanos, Maria A. Lobo, Melody Sadri-Naini, John Fiallos, Gilberto E. Sanchez, Teshia Bustos, Nikita Chintam, Marco Amaya, Susanne E. Strand, Alero Mayuku-Dore, Indira Sakibova, Grace Maria Nicole Biso, Alejandro DeFilippis, Daniela Bravo, Nevzat Tarhan, Carsten Claussen, Alejandro Mercado, Serge Braun, Louis Yuge, Shigeo Okabe, Farhad Taghizadeh-Hesary, Konstantin Kotliar, Christina Sadowsky, P. Sarat Chandra, Manjari Tripathi, Vasileios Katsaros, Brian Mehling, Maryam Noroozian, Kazem Abbasioun, Abbas Amirjamshidi, Gholam-Ali Hossein-Zadeh, Faridedin Naraghi, Mojtaba Barzegar, Ali A. Asadi-Pooya, Sajad Sahab-Negah, Saeid Sadeghian, Margaret Fahnestock, Nesrin Dilbaz, Namath Hussain, Zoltan Mari, Robert W. Thatcher, Daniel Sipple, Kuldip Sidhu, Deepak Chopra, Francesco Costa, Giannantonio Spena, Ted Berger, Deborah Zelinsky, Christopher J. Wheeler, J. Wesson Ashford, Reinhard Schulte, M. A. Nezami, Harry Kloor, Aaron Filler, Dawn S. Eliashiv, Dipen Sinha, Antonio A.F. DeSalles, Venkatraman Sadanand, Sergey Suchkov, Ken Green, Barish Metin, Robert Hariri, Jason Cormier, Vicky Yamamoto & Babak Kateb. (2021) Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. Journal of Alzheimer's Disease 83:4, pages 1563-1601.
Crossref
Crossref
Ran Zhou, Qiuming Zeng, Huan Yang, Yan Xu, Guojun Tan, Hongbo Liu, Lihua Wang, Hongyu Zhou, Meini Zhang, Jinzhou Feng, Tao Jin, Xinghu Zhang, Jiawei Wang, Xu Zhang, Feng Gao, Chunsheng Yang, Bitao Bu, Chunyang Li, Min Zhang, Huiqing Dong, Aiyu Lin, Weibin Liu, Lei Wu, Manxia Wang, Yulan Tang, Honghao Wang, Youming Long, Zhe Wang & Weihong Zheng. (2021) Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018. Frontiers in Neurology 12.
Crossref
Crossref
Aniket Mali, Apurva Sawant, Anagha Mahadik & Sujit Nair. 2021. Immunotherapy – A Novel Facet of Modern Therapeutics. Immunotherapy – A Novel Facet of Modern Therapeutics
63
115
.
Pieralessandro Lasalvia, Fabián Hernández, Camilo Castañeda-Cardona, J. Andrés Cuestas & Diego Rosselli. (2020) Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia. Value in Health Regional Issues 23, pages 13-18.
Crossref
Crossref
Maria Paz-Zulueta, Paula Parás-Bravo, David Cantarero-Prieto, Carla Blázquez-Fernández & Agustín Oterino-Durán. (2020) A literature review of cost-of-illness studies on the economic burden of multiple sclerosis.. Multiple Sclerosis and Related Disorders 43, pages 102162.
Crossref
Crossref
José M. García-Domínguez, Jorge Maurino, María L. Martínez-Ginés, Olga Carmona, Ana B. Caminero, Nicolás Medrano & Elena Ruíz-Beato. (2019) Economic burden of multiple sclerosis in a population with low physical disability. BMC Public Health 19:1.
Crossref
Crossref
Antoni Sicras-Mainar, Elena Ruíz-Beato, Ruth Navarro-Artieda & Jorge Maurino. (2017) Impact on healthcare resource utilization of multiple sclerosis in Spain. BMC Health Services Research 17:1.
Crossref
Crossref